Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor


Tytuł :
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Autorzy :
Hodi FS; Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Mihm MC
Soiffer RJ
Haluska FG
Butler M
Seiden MV
Davis T
Henry-Spires R
MacRae S
Willman A
Padera R
Jaklitsch MT
Shankar S
Chen TC
Korman A
Allison JP
Dranoff G
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2003 Apr 15; Vol. 100 (8), pp. 4712-7. Date of Electronic Publication: 2003 Apr 07.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Immunoconjugates*
Antibodies, Blocking/*therapeutic use
Antigens, Differentiation/*immunology
Cancer Vaccines/*therapeutic use
Melanoma/*immunology
Melanoma/*therapy
Ovarian Neoplasms/*immunology
Ovarian Neoplasms/*therapy
Abatacept ; Adult ; Aged ; Animals ; Antibodies, Monoclonal/therapeutic use ; Antigen Presentation ; Antigens, CD ; CD8-Positive T-Lymphocytes/immunology ; CTLA-4 Antigen ; Female ; Humans ; Male ; Melanoma/pathology ; Melanoma/secondary ; Mice ; Middle Aged ; Necrosis ; Ovarian Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Autorzy :
Korman A; Medarex Inc, 521 Cottonwood Drive, Milpitas, CA 95035, USA. />Yellin M
Keler T
Pokaż więcej
Źródło :
Current opinion in investigational drugs (London, England : 2000) [Curr Opin Investig Drugs] 2005 Jun; Vol. 6 (6), pp. 582-91.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antigens, Differentiation/*immunology
Cancer Vaccines/*therapeutic use
Immunotherapy, Active/*methods
Neoplasms/*therapy
Vaccines, Subunit/*therapeutic use
Animals ; Antibodies, Monoclonal/adverse effects ; Antigens, CD ; CTLA-4 Antigen ; Cancer Vaccines/adverse effects ; Clinical Trials as Topic ; Drug Evaluation, Preclinical ; Humans ; Neoplasms/immunology ; Vaccines, Subunit/adverse effects
Czasopismo naukowe
Tytuł :
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Autorzy :
Peggs KS; Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Quezada SA
Korman AJ
Allison JP
Pokaż więcej
Źródło :
Current opinion in immunology [Curr Opin Immunol] 2006 Apr; Vol. 18 (2), pp. 206-13. Date of Electronic Publication: 2006 Feb 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal*/immunology
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Antibodies, Neoplasm*/immunology
Antibodies, Neoplasm*/pharmacology
Antibodies, Neoplasm*/therapeutic use
Antigens, Differentiation/*immunology
Antigens, Neoplasm/*immunology
Immunotherapy/*methods
Neoplasms/*therapy
Animals ; Antigen-Antibody Reactions ; Antigens, CD ; Antigens, Differentiation/drug effects ; Antigens, Neoplasm/drug effects ; CTLA-4 Antigen ; Humans ; Models, Immunological ; Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Enhanced protein production by engineered zinc finger proteins.
Autorzy :
Reik A; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Boulevard, Richmond, CA 94804, USA.
Zhou Y
Collingwood TN
Warfe L
Bartsevich V
Kong Y
Henning KA
Fallentine BK
Zhang L
Zhong X
Jouvenot Y
Jamieson AC
Rebar EJ
Case CC
Korman A
Li XY
Black A
King DJ
Gregory PD
Pokaż więcej
Źródło :
Biotechnology and bioengineering [Biotechnol Bioeng] 2007 Aug 01; Vol. 97 (5), pp. 1180-9.
Typ publikacji :
Journal Article
MeSH Terms :
Genetic Enhancement/*methods
Protein Engineering/*methods
Recombinant Proteins/*biosynthesis
Transcription Factors/*genetics
Zinc Fingers/*genetics
Animals ; CHO Cells ; Cricetinae ; Cricetulus ; Promoter Regions, Genetic/genetics
Czasopismo naukowe
Tytuł :
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
Autorzy :
Wong RM; Department of Medicine, University of Southern California, 1441 Eastlake Avenue, Room 6428, Los Angeles, CA 90033, USA.
Scotland RR
Lau RL
Wang C
Korman AJ
Kast WM
Weber JS
Pokaż więcej
Źródło :
International immunology [Int Immunol] 2007 Oct; Vol. 19 (10), pp. 1223-34.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Lymphocyte Activation*
Antigens, Neoplasm/*immunology
Apoptosis Regulatory Proteins/*antagonists & inhibitors
Melanoma/*immunology
Skin Neoplasms/*immunology
T-Lymphocytes, Cytotoxic/*immunology
Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antigens, CD/analysis ; Antigens, CD/metabolism ; Apoptosis Regulatory Proteins/analysis ; Apoptosis Regulatory Proteins/metabolism ; Cytokines/metabolism ; Humans ; MART-1 Antigen ; Membrane Glycoproteins/immunology ; Neoplasm Proteins/immunology ; Programmed Cell Death 1 Receptor ; T-Lymphocytes, Cytotoxic/drug effects ; gp100 Melanoma Antigen
Czasopismo naukowe
Tytuł :
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Autorzy :
Hodi FS; Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. />Butler M
Oble DA
Seiden MV
Haluska FG
Kruse A
Macrae S
Nelson M
Canning C
Lowy I
Korman A
Lautz D
Russell S
Jaklitsch MT
Ramaiya N
Chen TC
Neuberg D
Allison JP
Mihm MC
Dranoff G
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2008 Feb 26; Vol. 105 (8), pp. 3005-10. Date of Electronic Publication: 2008 Feb 19.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antigens, CD/*immunology
Antigens, Differentiation/*immunology
Carcinoma/*therapy
Immunization, Passive/*methods
Melanoma/*therapy
Ovarian Neoplasms/*therapy
Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/immunology ; CTLA-4 Antigen ; Carcinoma/immunology ; Cohort Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Humans ; Ipilimumab ; Melanoma/immunology ; Ovarian Neoplasms/immunology ; T-Lymphocytes, Regulatory/immunology
Czasopismo naukowe
Tytuł :
High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.
Autorzy :
Rutebemberwa A; Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
Ray SC
Astemborski J
Levine J
Liu L
Dowd KA
Clute S
Wang C
Korman A
Sette A
Sidney J
Pardoll DM
Cox AL
Pokaż więcej
Źródło :
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2008 Dec 15; Vol. 181 (12), pp. 8215-25.
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD/*metabolism
Apoptosis Regulatory Proteins/*metabolism
Epitopes, T-Lymphocyte/*immunology
Hepacivirus/*immunology
Hepatitis C, Chronic/*immunology
T-Lymphocyte Subsets/*immunology
T-Lymphocyte Subsets/*virology
Virus Latency/*immunology
Acute Disease ; Adult ; Antigens, CD/biosynthesis ; Antigens, CD/genetics ; Antigens, Viral/immunology ; Apoptosis Regulatory Proteins/biosynthesis ; Apoptosis Regulatory Proteins/genetics ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/virology ; Epitopes, T-Lymphocyte/genetics ; Female ; Hepacivirus/genetics ; Hepatitis C, Chronic/virology ; Humans ; Mutation ; Programmed Cell Death 1 Receptor ; Prospective Studies ; RNA, Viral/genetics ; RNA, Viral/metabolism ; T-Lymphocyte Subsets/metabolism ; Viral Load ; Virus Latency/genetics
Czasopismo naukowe
Tytuł :
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Autorzy :
Li B; Cell Genesys, Inc., South San Francisco, California 94080, USA.
VanRoey M
Wang C
Chen TH
Korman A
Jooss K
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2009 Mar 01; Vol. 15 (5), pp. 1623-34. Date of Electronic Publication: 2009 Feb 10.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Apoptosis Regulatory Proteins/*antagonists & inhibitors
Colonic Neoplasms/*therapy
Granulocyte-Macrophage Colony-Stimulating Factor/*physiology
Melanoma, Experimental/*therapy
Animals ; Antibodies, Monoclonal/immunology ; Antigens, CD/immunology ; Antigens, CD/metabolism ; Apoptosis Regulatory Proteins/immunology ; Apoptosis Regulatory Proteins/metabolism ; Cell Proliferation ; Colonic Neoplasms/immunology ; Colonic Neoplasms/metabolism ; Cytokines/metabolism ; Drug Synergism ; Enzyme-Linked Immunosorbent Assay ; Lymphocytes, Tumor-Infiltrating/immunology ; Melanoma, Experimental/immunology ; Melanoma, Experimental/metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/immunology ; Neoplasm Proteins/metabolism ; Programmed Cell Death 1 Receptor ; Rats ; Recombinant Fusion Proteins/immunology ; T-Lymphocytes, Cytotoxic/immunology
Czasopismo naukowe
Tytuł :
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Autorzy :
Peggs KS; Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Quezada SA
Chambers CA
Korman AJ
Allison JP
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2009 Aug 03; Vol. 206 (8), pp. 1717-25. Date of Electronic Publication: 2009 Jul 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neoplasm/*therapeutic use
Antigens, CD/*immunology
T-Lymphocyte Subsets/*immunology
T-Lymphocytes, Regulatory/*immunology
Animals ; Antigens, CD/genetics ; CTLA-4 Antigen ; Cell Line, Tumor ; Humans ; Immunosuppression Therapy ; Immunotherapy ; In Vitro Techniques ; Melanoma, Experimental/immunology ; Melanoma, Experimental/therapy ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Transgenic ; Recombinant Proteins/genetics ; Recombinant Proteins/immunology
Czasopismo naukowe
Tytuł :
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Autorzy :
Wang W; Donald A Adam Comprehensive Melanoma Research Center, Department of Immunology and Immunotherapy, Moffitt Cancer Center, 12902 Magnolia Drive, SRB-24324, Tampa, FL 33612, USA. />Lau R
Yu D
Zhu W
Korman A
Weber J
Pokaż więcej
Źródło :
International immunology [Int Immunol] 2009 Sep; Vol. 21 (9), pp. 1065-77. Date of Electronic Publication: 2009 Aug 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antigens, CD/*immunology
Apoptosis Regulatory Proteins/*immunology
Melanoma/*immunology
Neoplasm Proteins/*immunology
T-Lymphocytes, Cytotoxic/*immunology
T-Lymphocytes, Regulatory/*immunology
Up-Regulation/*immunology
Antibodies/immunology ; Antibodies/pharmacology ; Apoptosis Regulatory Proteins/antagonists & inhibitors ; B7-H1 Antigen ; CD4 Antigens/immunology ; Humans ; Interleukin-2 Receptor alpha Subunit/immunology ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Staging ; Programmed Cell Death 1 Receptor ; T-Lymphocytes, Regulatory/metabolism
Czasopismo naukowe
Tytuł :
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Autorzy :
Mangsbo SM; Uppsala University, Sweden. />Sandin LC
Anger K
Korman AJ
Loskog A
Tötterman TH
Pokaż więcej
Źródło :
Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2010 Apr; Vol. 33 (3), pp. 225-35.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies/*immunology
Antigens, CD/*immunology
Antigens, Surface/*immunology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Apoptosis Regulatory Proteins/*immunology
Urinary Bladder Neoplasms/*drug therapy
Animals ; Antibodies/administration & dosage ; Antigens, Surface/genetics ; Antigens, Surface/metabolism ; Apoptosis Regulatory Proteins/genetics ; Apoptosis Regulatory Proteins/metabolism ; BCG Vaccine/administration & dosage ; BCG Vaccine/immunology ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; CTLA-4 Antigen ; Cell Line, Tumor ; Female ; Flow Cytometry ; Gene Expression Regulation, Neoplastic ; Lysosomal-Associated Membrane Protein 1/metabolism ; Mice ; Mice, Inbred C57BL ; Oligodeoxyribonucleotides/administration & dosage ; Programmed Cell Death 1 Receptor ; Reverse Transcriptase Polymerase Chain Reaction ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; Transforming Growth Factor beta/genetics ; Transforming Growth Factor beta/metabolism ; Treatment Outcome ; Tumor Burden/drug effects ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Autorzy :
Brahmer JR; Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Drake CG
Wollner I
Powderly JD
Picus J
Sharfman WH
Stankevich E
Pons A
Salay TM
McMiller TL
Gilson MM
Wang C
Selby M
Taube JM
Anders R
Chen L
Korman AJ
Pardoll DM
Lowy I
Topalian SL
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 Jul 01; Vol. 28 (19), pp. 3167-75. Date of Electronic Publication: 2010 Jun 01.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antigens, CD/*immunology
Apoptosis Regulatory Proteins/*immunology
Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Dose-Response Relationship, Drug ; Fatigue/chemically induced ; Female ; Humans ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Lymphopenia/chemically induced ; Male ; Melanoma/drug therapy ; Melanoma/pathology ; Middle Aged ; Neoplasms/pathology ; Nivolumab ; Programmed Cell Death 1 Receptor ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Autorzy :
Hoos A; Global Clinical Research, Oncology, Bristol-Myers Squibb Co, Wallingford, CT 06492, USA. />Ibrahim R
Korman A
Abdallah K
Berman D
Shahabi V
Chin K
Canetta R
Humphrey R
Pokaż więcej
Źródło :
Seminars in oncology [Semin Oncol] 2010 Oct; Vol. 37 (5), pp. 533-46.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antigens, CD/*immunology
Antineoplastic Agents/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/immunology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/immunology ; Biomarkers ; CTLA-4 Antigen ; Drug Evaluation ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Immune System Diseases/chemically induced ; Immune System Diseases/therapy ; Ipilimumab ; Melanoma/immunology ; Monitoring, Immunologic ; Practice Guidelines as Topic ; Skin Neoplasms/immunology ; Survival Analysis
Czasopismo naukowe
Tytuł :
PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
Autorzy :
Norde WJ; Departments of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Maas F
Hobo W
Korman A
Quigley M
Kester MG
Hebeda K
Falkenburg JH
Schaap N
de Witte TM
van der Voort R
Dolstra H
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2011 Aug 01; Vol. 71 (15), pp. 5111-22. Date of Electronic Publication: 2011 Jun 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Immunologic Memory*
Antigens, CD/*physiology
Apoptosis Regulatory Proteins/*physiology
Leukemia, Myeloid/*immunology
Neoplasm Proteins/*physiology
T-Lymphocyte Subsets/*immunology
Tumor Escape/*physiology
Apoptosis Regulatory Proteins/antagonists & inhibitors ; B7-1 Antigen/biosynthesis ; B7-2 Antigen/biosynthesis ; B7-H1 Antigen ; Coculture Techniques ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic/drug effects ; Humans ; Inflammation ; Interferon-gamma/pharmacology ; Leukemia, Myeloid/pathology ; Leukemia, Myeloid/surgery ; Minor Histocompatibility Antigens/immunology ; Neoplasm Proteins/antagonists & inhibitors ; Neoplastic Stem Cells/immunology ; Neoplastic Stem Cells/metabolism ; Programmed Cell Death 1 Receptor ; Receptors, Purinergic P2X5/immunology ; Recurrence ; T-Cell Antigen Receptor Specificity ; Transplantation, Homologous ; Tumor Escape/immunology ; Tumor Necrosis Factor-alpha/pharmacology
Czasopismo naukowe
Tytuł :
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.
Autorzy :
Bettini M; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Szymczak-Workman AL
Forbes K
Castellaw AH
Selby M
Pan X
Drake CG
Korman AJ
Vignali DA
Pokaż więcej
Źródło :
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2011 Oct 01; Vol. 187 (7), pp. 3493-8. Date of Electronic Publication: 2011 Aug 26.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antigens, CD/*immunology
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
Diabetes Mellitus, Type 1/*immunology
Animals ; Cell Separation ; Flow Cytometry ; Mice ; Mice, Inbred C57BL ; Mice, Inbred NOD ; Mice, Knockout
Czasopismo naukowe
Tytuł :
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Autorzy :
Woo SR; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Turnis ME
Goldberg MV
Bankoti J
Selby M
Nirschl CJ
Bettini ML
Gravano DM
Vogel P
Liu CL
Tangsombatvisit S
Grosso JF
Netto G
Smeltzer MP
Chaux A
Utz PJ
Workman CJ
Pardoll DM
Korman AJ
Drake CG
Vignali DA
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2012 Feb 15; Vol. 72 (4), pp. 917-27. Date of Electronic Publication: 2011 Dec 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD/*physiology
CD4-Positive T-Lymphocytes/*immunology
Neoplasms, Experimental/*immunology
Programmed Cell Death 1 Receptor/*physiology
Tumor Escape/*immunology
Animals ; Antibodies/therapeutic use ; Antigens, CD/immunology ; Cell Line, Tumor ; Drug Synergism ; Immune Tolerance/immunology ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Neoplasms, Experimental/pathology ; Neoplasms, Experimental/therapy ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
Autorzy :
Martinez Forero I; Centro de Investigacion Medica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain.
Okada H
Topalian SL
Gajewski TF
Korman AJ
Melero I
Pokaż więcej
Źródło :
Journal of translational medicine [J Transl Med] 2012 May 28; Vol. 10, pp. 108. Date of Electronic Publication: 2012 May 28.
Typ publikacji :
Congress
MeSH Terms :
Societies, Medical*
Immunotherapy/*methods
Neoplasms/*immunology
Neoplasms/*therapy
Animals ; Antibodies, Monoclonal/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Combined Modality Therapy ; Humans ; Immune System/immunology ; Immune System/pathology ; Mice ; Neoplasms/prevention & control
Tytuł :
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Autorzy :
Topalian SL; Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA. />Hodi FS
Brahmer JR
Gettinger SN
Smith DC
McDermott DF
Powderly JD
Carvajal RD
Sosman JA
Atkins MB
Leming PD
Spigel DR
Antonia SJ
Horn L
Drake CG
Pardoll DM
Chen L
Sharfman WH
Anders RA
Taube JM
McMiller TL
Xu H
Korman AJ
Jure-Kunkel M
Agrawal S
McDonald D
Kollia GD
Gupta A
Wigginton JM
Sznol M
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2012 Jun 28; Vol. 366 (26), pp. 2443-54. Date of Electronic Publication: 2012 Jun 02.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Renal Cell/drug therapy ; Colorectal Neoplasms/drug therapy ; Dose-Response Relationship, Drug ; Female ; Humans ; Ligands ; Male ; Melanoma/drug therapy ; Neoplasms/metabolism ; Nivolumab ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Prostatic Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Autorzy :
Brahmer JR; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
Tykodi SS
Chow LQ
Hwu WJ
Topalian SL
Hwu P
Drake CG
Camacho LH
Kauh J
Odunsi K
Pitot HC
Hamid O
Bhatia S
Martins R
Eaton K
Chen S
Salay TM
Alaparthy S
Grosso JF
Korman AJ
Parker SM
Agrawal S
Goldberg SM
Pardoll DM
Gupta A
Wigginton JM
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2012 Jun 28; Vol. 366 (26), pp. 2455-65. Date of Electronic Publication: 2012 Jun 02.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antineoplastic Agents/*administration & dosage
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Renal Cell/drug therapy ; Colorectal Neoplasms/drug therapy ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Melanoma/drug therapy ; Neoplasms/metabolism ; Nivolumab ; Ovarian Neoplasms/drug therapy ; Pancreatic Neoplasms/drug therapy ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Stomach Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Autorzy :
Hobo W; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
Norde WJ
Schaap N
Fredrix H
Maas F
Schellens K
Falkenburg JH
Korman AJ
Olive D
van der Voort R
Dolstra H
Pokaż więcej
Źródło :
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2012 Jul 01; Vol. 189 (1), pp. 39-49. Date of Electronic Publication: 2012 May 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
CD8-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*pathology
Receptors, Immunologic/*physiology
Antibodies, Blocking/physiology ; Antibodies, Blocking/therapeutic use ; CD8-Positive T-Lymphocytes/metabolism ; Cell Line, Tumor ; Epitopes, T-Lymphocyte/metabolism ; Gene Targeting/methods ; Humans ; Immunologic Memory ; Minor Histocompatibility Antigens/metabolism ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/immunology ; Receptors, Tumor Necrosis Factor, Member 14/physiology ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
Autorzy :
Turnis ME; Department of Immunology; St. Jude Children`s Research Hospital; Memphis, TN USA.
Korman AJ
Drake CG
Vignali DA
Pokaż więcej
Źródło :
Oncoimmunology [Oncoimmunology] 2012 Oct 01; Vol. 1 (7), pp. 1172-1174.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.
Autorzy :
Palmer BE; Division of Allergy and Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. />Neff CP
Lecureux J
Ehler A
Dsouza M
Remling-Mulder L
Korman AJ
Fontenot AP
Akkina R
Pokaż więcej
Źródło :
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2013 Jan 01; Vol. 190 (1), pp. 211-9. Date of Electronic Publication: 2012 Dec 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
CD4-Positive T-Lymphocytes/*immunology
CD4-Positive T-Lymphocytes/*virology
Down-Regulation/*immunology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Programmed Cell Death 1 Receptor/*physiology
Viral Load/*immunology
Animals ; B7-H1 Antigen/immunology ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/cytology ; HIV Infections/immunology ; HIV Infections/pathology ; HIV-1/growth & development ; HIV-1/immunology ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Knockout ; Programmed Cell Death 1 Receptor/biosynthesis ; Up-Regulation/immunology
Czasopismo naukowe
Tytuł :
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Autorzy :
Gardiner D; Bristol-Myers Squibb, Pennington, New Jersey, USA. />Lalezari J
Lawitz E
DiMicco M
Ghalib R
Reddy KR
Chang KM
Sulkowski M
Marro SO
Anderson J
He B
Kansra V
McPhee F
Wind-Rotolo M
Grasela D
Selby M
Korman AJ
Lowy I
Pokaż więcej
Źródło :
PloS one [PLoS One] 2013 May 22; Vol. 8 (5), pp. e63818. Date of Electronic Publication: 2013 May 22 (Print Publication: 2013).
Typ publikacji :
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antiviral Agents/*therapeutic use
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antiviral Agents/adverse effects ; Double-Blind Method ; Female ; Half-Life ; Hepacivirus/genetics ; Humans ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Nivolumab ; Programmed Cell Death 1 Receptor/metabolism ; RNA, Viral/genetics ; Viral Load/drug effects ; Viral Load/genetics
Czasopismo naukowe
Tytuł :
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Autorzy :
Selby MJ; Authors' Affiliation: Bristol-Myers Squibb Company, Redwood City, California.
Engelhardt JJ
Quigley M
Henning KA
Chen T
Srinivasan M
Korman AJ
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2013 Jul; Vol. 1 (1), pp. 32-42. Date of Electronic Publication: 2013 Apr 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacology
CTLA-4 Antigen/*immunology
Colonic Neoplasms/*therapy
Immunoglobulin G/*immunology
Immunoglobulin G/*pharmacology
T-Lymphocytes, Regulatory/*immunology
Animals ; Antibodies, Monoclonal/immunology ; CHO Cells ; Colonic Neoplasms/immunology ; Cricetulus ; Disease Models, Animal ; Female ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Random Allocation
Czasopismo naukowe
Tytuł :
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Autorzy :
Wolchok JD; Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. />Hodi FS
Weber JS
Allison JP
Urba WJ
Robert C
O'Day SJ
Hoos A
Humphrey R
Berman DM
Lonberg N
Korman AJ
Pokaż więcej
Źródło :
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2013 Jul; Vol. 1291, pp. 1-13. Date of Electronic Publication: 2013 Jun 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Animals ; Antibodies, Monoclonal/immunology ; Antineoplastic Agents/immunology ; Clinical Trials as Topic/methods ; Humans ; Immunotherapy/methods ; Ipilimumab ; Melanoma/immunology ; Melanoma/mortality ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Survival Rate/trends ; Treatment Outcome
Czasopismo naukowe
Tytuł :
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Autorzy :
Wang C; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Thudium KB; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Han M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wang XT; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Huang H; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Feingersh D; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Garcia C; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wu Y; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Kuhne M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Srinivasan M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Singh S; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wong S; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Garner N; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Leblanc H; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Bunch RT; Bristol-Myers Squibb Company, Mount Vernon, Indiana; and.
Blanset D; Medarex, Princeton, New Jersey.
Selby MJ; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California; alan.korman@bms.com.
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2014 Sep; Vol. 2 (9), pp. 846-56. Date of Electronic Publication: 2014 May 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*immunology
Lymphocyte Activation/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Programmed Cell Death 1 Receptor/*immunology
Animals ; Antibodies, Monoclonal/biosynthesis ; Antigen-Presenting Cells/immunology ; Cell Line, Tumor ; Female ; Humans ; Immunotherapy ; Macaca fascicularis ; Male ; Mice ; Mice, Transgenic ; Neoplasms/therapy ; Nivolumab ; Toxicity Tests ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Autorzy :
Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Zhang X; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schuster H; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Caron E; Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland.
Ward JP; 1] Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA [2] Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Ivanova Y; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Hundal J; The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA.
Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Krebber WJ; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
Mulder GE; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
Toebes M; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Vesely MD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Lam SS; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, California 94063, USA.
Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Sharpe AH; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Pearce EL; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schumacher TN; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Aebersold R; 1] Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland [2] Faculty of Science, University of Zurich, Zurich, 8093 Zurich, Switzerland.
Rammensee HG; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Melief CJ; 1] ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands [2] Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Mardis ER; 1] The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA [2] Department of Genetics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Gillanders WE; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Artyomov MN; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Pokaż więcej
Źródło :
Nature [Nature] 2014 Nov 27; Vol. 515 (7528), pp. 577-81.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Antigens, Neoplasm/*genetics
Antigens, Neoplasm/*immunology
CD8-Positive T-Lymphocytes/*immunology
Cancer Vaccines/*therapeutic use
Cell Cycle Checkpoints/*immunology
Sarcoma/*therapy
Animals ; Epitopes/genetics ; Male ; Mice ; Sarcoma/immunology ; Vaccines, Synthetic/therapeutic use
Czasopismo naukowe
Tytuł :
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :
Hannani D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vétizou M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Enot D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France.
Rusakiewicz S; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chaput N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Klatzmann D; 1] INSERM, Unité Mixte de Recherche_S959, I, Paris, France [2] Assistance-Publique Hopitaux de Paris, Hôpital Pitié-Salpêtrière, Biotherapy, Paris, France.
Desbois M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Jacquelot N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vimond N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chouaib S; INSERM U753, Villejuif, France.
Mateus C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] Department of Medical Oncology, IGR, Villejuif, France.
Allison JP; Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
Ribas A; University of California Los Angeles, Los Angeles, CA, USA.
Wolchok JD; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yuan J; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Wong P; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Postow M; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mackiewicz A; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Mackiewicz J; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Schadendorff D; Department of Dermatology, University Hospital Essen, Germany.
Jaeger D; National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
Zörnig I
Hassel J
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, USA.
Bahjat K; Earle A Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Maio M; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Calabro L; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Teng MW; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Smyth MJ; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Eggermont A; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] INSERM U981, Villejuif, France.
Robert C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Department of Medical Oncology, IGR, Villejuif, France [4] INSERM U981, Villejuif, France.
Kroemer G; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France [4] Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France [6] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Zitvogel L; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France [4] Department of Medical Oncology, IGR, Villejuif, France.
Pokaż więcej
Źródło :
Cell research [Cell Res] 2015 Feb; Vol. 25 (2), pp. 208-24. Date of Electronic Publication: 2015 Jan 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*metabolism
Interleukin-2 Receptor alpha Subunit/*blood
Melanoma/*pathology
Receptors, Interleukin-2/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CTLA-4 Antigen/immunology ; Cohort Studies ; Disease Models, Animal ; Female ; Humans ; Immunotherapy ; Interleukin-2 Receptor alpha Subunit/immunology ; Ipilimumab ; Male ; Melanoma/mortality ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Receptors, Interleukin-2/genetics ; Receptors, Interleukin-2/immunology ; Recombinant Proteins/biosynthesis ; Recombinant Proteins/genetics ; Recombinant Proteins/pharmacology ; T-Lymphocytes, Regulatory/immunology ; Up-Regulation/drug effects ; Young Adult
Czasopismo naukowe
Tytuł :
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :
Hannani D
Vétizou M
Enot D
Rusakiewicz S
Chaput N
Klatzmann D
Desbois M
Jacquelot N
Vimond N
Chouaib S
Mateus C
Allison JP
Ribas A
Wolchok JD
Yuan J
Wong P
Postow M
Mackiewicz A
Mackiewicz J
Schadendorff D
Jaeger D
Korman AJ
Bahjat K
Maio M
Calabro L
Teng MW
Smyth MJ
Eggermont A
Robert C
Kroemer G
Zitvogel L
Pokaż więcej
Źródło :
Cell research [Cell Res] 2015 Mar; Vol. 25 (3), pp. 399-400.
Typ publikacji :
Published Erratum
Tytuł :
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.
Autorzy :
Berman D; Bristol-Myers Squibb, Research and Development Division, United States.
Korman A; Bristol-Myers Squibb, Research and Development Division, United States.
Peck R; Bristol-Myers Squibb, Research and Development Division, United States.
Feltquate D; Bristol-Myers Squibb, Research and Development Division, United States.
Lonberg N; Bristol-Myers Squibb, Research and Development Division, United States.
Canetta R; Bristol-Myers Squibb, Research and Development Division, United States. Electronic address: .
Pokaż więcej
Źródło :
Pharmacology & therapeutics [Pharmacol Ther] 2015 Apr; Vol. 148, pp. 132-53. Date of Electronic Publication: 2014 Dec 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Immunologic Factors/*therapeutic use
Neoplasms/*drug therapy
Animals ; Antibodies, Monoclonal/adverse effects ; Humans ; Immunologic Factors/adverse effects
Czasopismo naukowe
Tytuł :
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Autorzy :
Chauvin JM
Pagliano O
Fourcade J
Sun Z
Wang H
Sander C
Kirkwood JM
Chen TH
Maurer M
Korman AJ
Zarour HM
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2015 May; Vol. 125 (5), pp. 2046-58. Date of Electronic Publication: 2015 Apr 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, Neoplasm/*immunology
CD8-Positive T-Lymphocytes/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Melanoma/*immunology
Neoplasm Proteins/*physiology
Programmed Cell Death 1 Receptor/*physiology
Receptors, Immunologic/*physiology
Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antigen-Presenting Cells/immunology ; Antigen-Presenting Cells/metabolism ; Antigens, Differentiation, T-Lymphocyte/biosynthesis ; Antigens, Differentiation, T-Lymphocyte/genetics ; CD8-Positive T-Lymphocytes/metabolism ; Cell Line, Tumor ; Cytokines/biosynthesis ; Gene Expression Regulation, Neoplastic ; Humans ; Immunologic Memory ; Immunophenotyping ; Interleukin-2 Receptor beta Subunit/biosynthesis ; Interleukin-2 Receptor beta Subunit/genetics ; Lymphocyte Activation ; Lymphocytes, Tumor-Infiltrating/metabolism ; Melanoma/pathology ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/biosynthesis ; Programmed Cell Death 1 Receptor/genetics ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/biosynthesis ; Receptors, Immunologic/genetics ; Receptors, Virus/biosynthesis ; Receptors, Virus/genetics ; T-Cell Antigen Receptor Specificity ; Up-Regulation
Czasopismo naukowe
Tytuł :
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Autorzy :
Melero I; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Berman DM; Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA.
Aznar MA; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Korman AJ; Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA.
Pérez Gracia JL; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Haanen J; The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Nature reviews. Cancer [Nat Rev Cancer] 2015 Aug; Vol. 15 (8), pp. 457-72.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy*
Neoplasms/*therapy
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; Combined Modality Therapy ; Humans ; Molecular Targeted Therapy ; Neoplasms/immunology ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Autorzy :
Sanmamed MF; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Rodriguez I; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Schalper KA; Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Oñate C; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Azpilikueta A; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Rodriguez-Ruiz ME; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Morales-Kastresana A; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Labiano S; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Pérez-Gracia JL; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Martín-Algarra S; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Alfaro C; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Mazzolini G; Gene Therapy Laboratory, Department of Medicine, Universidad Austral, Pilar, Argentina.
Sarno F; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
Hidalgo M; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain. Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Jure-Kunkel M; Bristol-Myers Squibb Company, Princeton, New Jersey.
Melero I; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2015 Sep 01; Vol. 75 (17), pp. 3466-78. Date of Electronic Publication: 2015 Jun 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Colorectal Neoplasms/*immunology
DNA-Binding Proteins/*genetics
Interleukin Receptor Common gamma Subunit/*genetics
Programmed Cell Death 1 Receptor/*biosynthesis
T-Lymphocytes/*drug effects
Tumor Necrosis Factor Receptor Superfamily, Member 9/*biosynthesis
Animals ; Antibodies, Monoclonal/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; DNA-Binding Proteins/immunology ; Graft vs Host Disease/immunology ; Graft vs Host Disease/pathology ; HT29 Cells ; Humans ; Interleukin Receptor Common gamma Subunit/immunology ; Leukocytes, Mononuclear/immunology ; Lymphocyte Activation/immunology ; Mice ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; T-Lymphocytes/pathology ; Tumor Necrosis Factor Receptor Superfamily, Member 9/antagonists & inhibitors ; Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
Czasopismo naukowe
Tytuł :
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Autorzy :
Dahan R; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA.
Sega E; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Engelhardt J; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Selby M; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Ravetch JV; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA. Electronic address: .
Pokaż więcej
Źródło :
Cancer cell [Cancer Cell] 2015 Sep 14; Vol. 28 (3), pp. 285-95.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies/*immunology
B7-H1 Antigen/*immunology
Neoplasms/*immunology
Programmed Cell Death 1 Receptor/*immunology
Receptors, IgG/*immunology
Animals ; Cell Line, Tumor ; Ligands ; Mice ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Autorzy :
Koguchi Y; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Hoen HM; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Bambina SA; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Rynning MD; R&D Systems, Minneapolis, Minnesota.
Fuerstenberg RK; R&D Systems, Minneapolis, Minnesota.
Curti BD; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Urba WJ; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Milburn C; Bristol-Myers Squibb, Redwood City, California.
Bahjat FR; Bristol-Myers Squibb, Redwood City, California.
Korman AJ; Bristol-Myers Squibb, Redwood City, California.
Bahjat KS; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2015 Dec 01; Vol. 75 (23), pp. 5084-92.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Chemokine CXCL11/*blood
Histocompatibility Antigens Class I/*blood
Melanoma/*blood
Melanoma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Cancer Vaccines/therapeutic use ; Female ; Humans ; Ipilimumab ; Kaplan-Meier Estimate ; Male ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł :
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
Autorzy :
Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Hammond KB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Clayton KL; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Ishii N; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abdel-Mohsen M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Liegler T; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Mitchell BI; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hecht FM; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Shikuma CM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Maurer M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Pokaż więcej
Źródło :
PLoS pathogens [PLoS Pathog] 2016 Jan 07; Vol. 12 (1), pp. e1005349. Date of Electronic Publication: 2016 Jan 07 (Print Publication: 2016).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
Receptors, Immunologic/*immunology
Animals ; B7-H1 Antigen/immunology ; Cell Separation ; DNA, Viral/analysis ; Disease Progression ; Flow Cytometry ; Humans ; Lymphocyte Activation/immunology ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/immunology
Czasopismo naukowe
Tytuł :
The Human Vaccines Project: A roadmap for cancer vaccine development.
Autorzy :
Romero P; Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland.
Banchereau J; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Bhardwaj N; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cockett M; Bristol-Myers Squibb, Wallingford, CT06492, USA.
Disis ML; University of Washington School of Medicine, Seattle, WA 98109-4714, USA.
Dranoff G; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
Gilboa E; Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.
Hammond SA; MedImmune, Gaithersburg, MD 20878, USA.
Hershberg R; Celgene Immuno-Oncology Center of Excellence, 1616 Eastlake Avenue, Suite 500, Seattle, WA 98102, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Kvistborg P; Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.
Melief C; ISA Pharmaceuticals & Leiden University Medical Center, 2333 ZA Leiden, Netherlands.
Mellman I; Genentech, San Francisco, CA 94080, USA.
Palucka AK; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA. Baylor Institute for Immunology Research, Dallas, TX 75204, USA.
Redchenko I; Oxford University, Oxford OX3 7DQ, UK.
Robins H; Adaptive Biotechnologies, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA.
Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Schenkelberg T; West Monument Consulting, 1906 R Street NW Street 11, Washington, DC 20009, USA.
Schoenberger S; Center for Personalized Cancer Immunotherapy, La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center, La Jolla, San Diego, CA 92037, USA.
Sosman J; Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.
Türeci Ö; CI3 Cluster for Individualized Immunotherapy, Kupferbergterasse 17-19, 55131 Mainz, Germany.
Van den Eynde B; Ludwig Institute for Cancer Research, Brussels branch, Brussels, BRU 1200, Belgium. Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Woluwe-Saint-Lambert, Belgium. University of Oxford, Nuffield Department of Medicine, Ludwig Institute for Cancer Research, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Koff W; International AIDS Vaccines Initiative, 125 Broad Street, 9th Floor, New York, NY 10004, USA.
Coukos G; Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland. .
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2016 Apr 13; Vol. 8 (334), pp. 334ps9.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cancer Vaccines/*immunology
Antigens, Neoplasm/immunology ; Humans ; Immunologic Memory ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Autorzy :
Houot R; Department of Hematology, CHU de Rennes , Rennes, France.
Gaulard P; Department of Pathology, Inserm U955, Université Paris-Est, CHU Henri Mondor , Créteil, France.
Schreiber R; Department of Pathology and Immunology, Washington University , St. Louis, MO, USA.
Mellman I; Genentech , South San Francisco, CA, USA.
Lambotte O; Department of Clinical Immunology and Internal Medicine, Hospital Kremlin Bicêtre, Université Paris-Sud , Orsay, France.
Coulie PG; de Duve Institute, Université Catholique de Louvain , Brussels, Belgium.
Fest T; Inserm U917, CHU de Rennes , Rennes, France.
Korman A; Bristol-Myers Squibb , CA, USA.
Levy R; Stanford School of Medicine , Stanford, CA, USA.
Shipp M; Dana-Farber Cancer Institute , Boston, MA, USA.
Tarte K; Inserm U917, CHU de Rennes , Rennes, France.
Kohrt H; Department of Medicine, Stanford School of Medicine , Stanford, CA, USA.
Marabelle A; Gustave Roussy Cancer Campus , Villejuif, France.
Ansell S; Division of Hematology , Mayo Clinic, Rochester, MN, USA.
Watier H; CHRU de Tours, Université François-Rabelais and CNRS, UMR7292 , Tours, France.
van Elsas A; Aduro Biotech Europe , Oss, The Netherlands.
Balakumaran A; Clinical Research-Oncology , Merck & Co , Kenilworth, NJ, USA.
Arce Vargas F; UCL Cancer Institute, University College of London , London, UK.
Quezada SA; UCL Cancer Institute, University College of London , London, UK.
Salles G; Department of Hematology, Université Claude Bernard, Hospices Civils de Lyon , INSERM 1052 , Lyon, France.
Olive D; Inserm UMR 1068, Institut Paoli Calmettes, Aix Marseille Université , Marseille, France.
Pokaż więcej
Źródło :
Oncoimmunology [Oncoimmunology] 2016 May 19; Vol. 5 (7), pp. e1186323. Date of Electronic Publication: 2016 May 19 (Print Publication: 2016).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Autorzy :
Dahan R; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA.
Barnhart BC; Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City, CA 94063, USA.
Li F; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA.
Yamniuk AP; Bristol-Myers Squibb, Department of Molecular Discovery Technologies, Princeton, NJ 08543, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City, CA 94063, USA.
Ravetch JV; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA. Electronic address: .
Pokaż więcej
Źródło :
Cancer cell [Cancer Cell] 2016 Jun 13; Vol. 29 (6), pp. 820-831. Date of Electronic Publication: 2016 Jun 02.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
CD40 Antigens/*agonists
Neoplasms/*drug therapy
Receptors, IgG/*immunology
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/immunology ; Cell Line, Tumor ; Humans ; Immunotherapy ; Mice ; Neoplasms/immunology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
Autorzy :
Morris ZS; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. .
Guy EI; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Francis DM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Gressett MM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Werner LR; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Carmichael LL; Department of Biostatistics and Bioinformatics, University of Wisconsin, Madison, Wisconsin.
Yang RK; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Armstrong EA; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Huang S; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Navid F; Department of Oncology, St. Jude Children's Hospital, Memphis, Tennessee.
Gillies SD; Provenance Biopharmaceuticals, Carlisle, Massachusetts.
Korman A; Bristol Myers Squibb, Redwood, California.
Hank JA; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Rakhmilevich AL; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Harari PM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Sondel PM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. Department of Pediatrics, University of Wisconsin, Madison, Wisconsin. Department of Genetics, University of Wisconsin, Madison, Wisconsin.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2016 Jul 01; Vol. 76 (13), pp. 3929-41. Date of Electronic Publication: 2016 May 06.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacology
CTLA-4 Antigen/*immunology
Interleukin-2/*immunology
Lung Neoplasms/*therapy
Melanoma, Experimental/*therapy
Pancreatic Neoplasms/*therapy
Animals ; Apoptosis/drug effects ; Apoptosis/radiation effects ; Blotting, Western ; Cell Proliferation/drug effects ; Cell Proliferation/radiation effects ; Chemoradiotherapy ; Combined Modality Therapy ; Female ; Humans ; Immunoenzyme Techniques ; Lung Neoplasms/immunology ; Lung Neoplasms/secondary ; Melanoma, Experimental/immunology ; Melanoma, Experimental/pathology ; Mice ; Mice, Inbred C57BL ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/pathology ; T-Lymphocytes/immunology ; Tumor Cells, Cultured ; Vaccination ; X-Rays ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :
Selby MJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Engelhardt JJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Johnston RJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Lu LS; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Han M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Thudium K; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Yao D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Quigley M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Valle J; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Wang C; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Chen B; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Cardarelli PM; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Blanset D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0161779. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Melanoma/*drug therapy
Animals ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/metabolism ; Cell Line, Tumor ; Cells, Cultured ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Disease Models, Animal ; Female ; Humans ; Ipilimumab ; Lymphocytes/immunology ; Lymphocytes/metabolism ; Macaca fascicularis ; Melanoma/metabolism ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/metabolism
Czasopismo naukowe
Tytuł :
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.
Autorzy :
Ngiow SF; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. .; School of Medicine, University of Queensland, Herston, Queensland, Australia.
Young A; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, University of Queensland, Herston, Queensland, Australia.
Blake SJ; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Hill GR; Bone Marrow Transplant Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Butterfield St, Brisbane, Queensland, Australia.
Yagita H; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Teng MW; School of Medicine, University of Queensland, Herston, Queensland, Australia.; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Korman AJ; Bristol Myers Squibb Company, Redwood City, California.
Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. .; School of Medicine, University of Queensland, Herston, Queensland, Australia.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2016 Nov 01; Vol. 76 (21), pp. 6266-6277. Date of Electronic Publication: 2016 Sep 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
CD40 Antigens/*antagonists & inhibitors
Interleukin-12/*physiology
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes/*physiology
Animals ; Interleukin-23/physiology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Neoplasms/immunology ; T-Lymphocytes, Regulatory/physiology
Czasopismo naukowe
Tytuł :
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :
Selby MJ
Engelhardt JJ
Johnston RJ
Lu LS
Han M
Thudium K
Yao D
Quigley M
Valle J
Wang C
Chen B
Cardarelli PM
Blanset D
Korman AJ
Pokaż więcej
Źródło :
PloS one [PLoS One] 2016 Nov 18; Vol. 11 (11), pp. e0167251. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2016).
Typ publikacji :
Published Erratum
Tytuł :
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Autorzy :
Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Ward JP; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Lee SH; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Hundal J; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Selby MJ; Bristol-Myers Squibb, Redwood City, California.
Graziano RF; Bristol-Myers Squibb, Lawrenceville, New Jersey.
Mardis ER; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Korman AJ; Bristol-Myers Squibb, Redwood City, California.
Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri. .; Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, Missouri.
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2017 Feb; Vol. 5 (2), pp. 106-117. Date of Electronic Publication: 2017 Jan 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms :
Gene Expression*
B7-H1 Antigen/*genetics
Neoplasms/*genetics
Neoplasms/*immunology
Tumor Escape/*genetics
Tumor Escape/*immunology
Animals ; Cell Line, Tumor ; Cell Proliferation ; Disease Models, Animal ; Female ; Gene Knockout Techniques ; Genes, MHC Class I/genetics ; Genes, MHC Class I/immunology ; Humans ; Male ; Mice ; Mutation ; Neoplasms/pathology ; Sarcoma/genetics ; Sarcoma/immunology ; Sarcoma/pathology ; Tumor Burden ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies